CeQur sets up Wales unit; to launch new insulin device in Europe, US in 2016

1 September 2015

CeQur on Tuesday said it has set up a unit in Wales following another round of $100 million investment from Arthurian Life Sciences and that it plans to launch its new insulin infusion device in Europe and the USA in 2016.

The company said the funds will also be used to conduct clinical studies, manufacturing scale-up and commercial operations for a planned European and US 2016 launch of its device PaQ.

CeQur is preparing to launch its fully optimized, second-generation PaQ and has established a UK subsidiary in Wales. One of the company's first activities in Wales will be a clinical study in collaboration with University of Swansea scheduled to begin enrolment in 2016.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >